S-1/A: Impact BioMedical Inc. Eyes Public Markets with $7 Million IPO

Impact BioMedical Inc. plans to raise approximately $7 million through an initial public offering of 2,000,000 shares of common stock.

Summary

• Impact BioMedical Inc., a subsidiary of DSS, Inc., is planning an initial public offering of 2,000,000 shares of its common stock.
• The anticipated IPO price is between $3.00 and $5.00 per share, with an expected net proceeds of approximately $7.026 million, or $8.118 million if the underwriter's over-allotment option is fully exercised.
• The company intends to list its shares on the NYSE American under the symbol IBO.
• The IPO includes an underwriter option to purchase an additional 300,000 shares and the issuance of warrants to the underwriter to purchase 10% of the shares sold in the offering.
• Net proceeds will be used for research and development (30%), potential acquisitions (up to 10%), and general working capital.
• Impact BioMedical is an emerging growth company and a smaller reporting company, which allows it to take advantage of reduced reporting requirements.
• The company's business model focuses on discovering, confirming, and patenting unique science and technologies for human healthcare and wellness, with a focus on licensing and strategic partnerships.
• Key technologies include Linebacker (oncology, inflammatory disorders, neurology), Laetose (sugar alternative), Functional Fragrance Formulation (antimicrobial, insect repellent), and Equivir (antiviral).
• The company has a history of operating losses and relies on funding from its parent company, DSS, Inc.
• A revolving promissory note with DSS, amended in January 2024, extends the maturity to September 30, 2030, with interest calculated at the Wall Street Journal prime rate plus 0.50%.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has promising technologies and partnerships, its financial performance and going concern status raise concerns. The IPO is a positive step, but its success is not guaranteed.

Positives

• The company has several unique and proprietary technologies in continuing development.
• Two compounds from the Linebacker platform (LB-1, LB-2) are licensed to ProPhase Laboratories (NASDAQ: PRPH) for clinical development and commercialization for which Impact Biomedical could receive future milestone payments and royalties.
• Laetose has a unique composition patent allowed in the United States and patents are pending in other countries worldwide.
• Composition patents have issued in the U.S. and are pending in other countries for Functional Fragrance Formulation (3F).
• Method and composition patents are issued in the U.S. and other countries for Equivir/Equivir G.
• The company has been approved by the NYSE American for listing on its exchange.

Negatives

• The company has incurred operating losses and negative cash flows over the past two years, raising substantial doubt about its ability to continue as a going concern.
• The company is a human healthcare and consumer wellness company with no significant revenue.
• The company is dependent on its collaborative agreements for the development of products and business development, which exposes us to the risk of reliance on the viability of third parties.
• The company faces significant competition from other biopharmaceutical and consumer product companies.
• The company may not have adequate funds to implement its business plan.
• The company's ability to resell and/or license our products will depend upon successful clinical trials.
• The company will rely on third parties for manufacturing of our clinical drug supplies; our dependence on these manufacturers may impair the development of our drug candidates.

Risks

• The company may not have adequate funds to implement its business plan.
• The company's ability to resell and/or license our products will depend upon successful clinical trials.
• The company faces significant competition from other biopharmaceutical and consumer product companies.
• The company is dependent on its collaborative agreements for the development of products and business development, which exposes us to the risk of reliance on the viability of third parties.
• The company is increasingly dependent on information technology systems to operate our business and a cyber-attack or other breach of our systems, or those of third parties on whom we may rely, could subject us to liability or interrupt the operation of our business.
• The company may be unable to adequately or cost-effectively protect or enforce our intellectual property rights, thereby weakening our competitive position and increasing operating costs.
• The market price of our common stock may be highly volatile, and you could lose all or part of your investment.
• Our management will have broad discretion over the use of any net proceeds from this offering and you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.
• Investors in this offering may experience future dilution as a result of this and future equity offerings.
• An active trading market for our common stock may not develop, and you may not be able to sell your common stock at or above the initial public offering price.

Future Outlook

The company expects to continue to incur significant operating losses and anticipates that its losses may increase substantially as it expands its drug development programs.

Industry Context

The announcement reflects a trend of smaller biomedical companies seeking public funding to advance their research and development efforts. The success of Impact BioMedical will depend on its ability to navigate the competitive landscape and secure partnerships for commercialization.

Comparison to Industry Standards

• It is difficult to compare Impact BioMedical to industry standards due to its early stage and lack of significant revenue.
• Comparable companies in the biopharmaceutical sector often have established revenue streams or late-stage clinical assets.
• For example, ProPhase Labs, Inc. (NASDAQ: PRPH), which has licensing agreements with Impact BioMedical, is a more established company with a diverse portfolio of products and revenue streams.
• Other comparable companies include early-stage biotech firms focusing on specific therapeutic areas, such as oncology or neurology, but their valuations and financial metrics vary widely depending on their pipeline and clinical progress.

Corporate Governance

Related Party Transactions

• The company has a revolving promissory note with DSS, a related party, which accrues interest at a rate of 4.25% and is due in full at the maturity date of September 30, 2030.
• The company incurred expenses to GRDG, a related party, for research and development activities.
• The company entered into a Licensing Proceeds Distribution Agreement with GRDG Sciences, LLC (GRDG), Global BioLife, Inc., and Impact BioLife Sciences, Inc.

Stakeholder Impact

• Shareholders: Potential dilution from the IPO and future equity offerings.
• Employees: Job security dependent on the company's ability to secure funding and achieve profitability.
• Customers: Access to new healthcare and wellness products if the company's technologies are successfully commercialized.
• Suppliers: Potential for increased business if the company's operations expand.
• Creditors: Repayment of debt dependent on the company's financial performance.

Next Steps

• The company intends to use the net proceeds received from this offering for general and working capital purposes, including but not limited to investing in research and development, including in our technology, the repayment of debt and for working capital and general corporate purposes.
• The company intends to apply to list shares of our common stock on the NYSE American, subject to official notice of issuance, under the symbol IBO.

Key Dates

Keywords

IPO, initial public offering, Impact BioMedical, common stock, underwriter, Securities, biopharmaceutical, licensing, pharmaceutical, healthcare, biomedical